# A Study to Assess the Efficacy and Safety of Advagraf® Switching From Cyclosporine Between the Group That Was Treated With a 50% Reduced Corticosteroid and the Group With Maintained Corticosteroid for Stable Kidney Transplant Recipients

> **NCT02034747** · PHASE4 · COMPLETED · sponsor: **Astellas Pharma Korea, Inc.** · enrollment: 150 (actual)

## Conditions studied

- Kidney Transplant

## Interventions

- **DRUG:** Advagraf
- **DRUG:** Corticosteroid

## Key facts

- **NCT ID:** NCT02034747
- **Lead sponsor:** Astellas Pharma Korea, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11-21
- **Primary completion:** 2015-11-07
- **Final completion:** 2015-11-07
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2024-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02034747

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02034747, "A Study to Assess the Efficacy and Safety of Advagraf® Switching From Cyclosporine Between the Group That Was Treated With a 50% Reduced Corticosteroid and the Group With Maintained Corticosteroid for Stable Kidney Transplant Recipients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02034747. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*